Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Depreciation: 2015-2025

Historic Accumulated Depreciation for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $56.4 million.

  • Seres Therapeutics' Accumulated Depreciation rose 8.06% to $56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year increase of 8.06%. This contributed to the annual value of $53.2 million for FY2024, which is 8.39% up from last year.
  • Latest data reveals that Seres Therapeutics reported Accumulated Depreciation of $56.4 million as of Q3 2025, which was up 1.89% from $55.3 million recorded in Q2 2025.
  • Seres Therapeutics' Accumulated Depreciation's 5-year high stood at $56.4 million during Q3 2025, with a 5-year trough of $35.8 million in Q1 2021.
  • In the last 3 years, Seres Therapeutics' Accumulated Depreciation had a median value of $52.4 million in 2024 and averaged $51.9 million.
  • Data for Seres Therapeutics' Accumulated Depreciation shows a peak YoY increased of 21.17% (in 2021) over the last 5 years.
  • Over the past 5 years, Seres Therapeutics' Accumulated Depreciation (Quarterly) stood at $40.3 million in 2021, then climbed by 11.85% to $45.0 million in 2022, then grew by 8.97% to $49.1 million in 2023, then grew by 8.39% to $53.2 million in 2024, then grew by 8.06% to $56.4 million in 2025.
  • Its last three reported values are $56.4 million in Q3 2025, $55.3 million for Q2 2025, and $54.3 million during Q1 2025.